ABSTRAK
Kanker paru adalah salah satu jenis kanker dengan prevalensi dan mortalitas yang tinggi di dunia. Beberapa studi klinis menunjukkan bahwa
metformin dapat menurunkan angka mortalitas berbagai jenis kanker, termasuk kanker paru. Metformin dapat menghambat berbagai jaras
persinyalan, seperti Insulin-like Growth Factor Receptor (IGF-1R), Epidermal Growth Factor Receptor (EGFR), dan mammalian Target of Rapamycin
(mTOR), yang berperan dalam pertumbuhan dan proliferasi sel kanker. Selain itu, metformin juga memiliki efek sinergis dengan kemoterapi
standar, yaitu dapat meningkatkan survival rate serta mengurangi dosis kemoterapi. Masih diperlukan penelitian lebih lanjut untuk mengetahui
potensi kombinasinya dengan kemoterapi standar pada pengobatan kanker paru.
Kata kunci: Jaras persinyalan, kanker paru, kemoterapi, metformin
ABSTRACT
Lung cancer is one of the most prevalent and highest mortality cancers in the world. Several studies show that metformin can lower the
mortality of several cancers, including lung cancer. Metformin can block several signaling pathways such as Insulin-like Growth Factor Receptor
(IGF-1R), Epidermal Growth Factor Receptor (EGFR), and mammalian Target of Rapamycin (mTOR), which are responsible for the growth and
proliferation of cell. Metformin is synergistic with standard chemotherapy, improves survival rate, and lowers the chemotherapy dose. Further
study is needed to evaluate further potential of this drug. Vito Filbert Jayalie, Andy William, Shelly, Cosphiadi Irawan. Metformin as Insulin-like
Growth Factor-1 Receptor (IGF-1R), Epidermal Growth Factor Receptor (EGFR), and Mammalian Target of Rapamycin (mTOR) Inhibitor for
Lung Cancer Chemoterapy.
Keywords: Chemotherapy, lung cancer, metformin, signaling pathway
PENDAHULUAN
Kanker merupakan salah satu penyebab
utama kematian di dunia dengan jumlah
kasus yang terus bertambah. Prevalensi kanker
di dunia pada tahun 2012 adalah sekitar 32,6
juta kasus dengan kasus baru sebanyak 14,1
juta kasus dan 8,2 juta kasus meninggal. Pada
tahun 2032 diperkirakan akan terdapat 22 juta
kasus baru kanker setiap tahunnya.1 Salah satu
jenis kanker yang banyak menarik perhatian
selama beberapa dekade terakhir adalah
Alamat Korespondensi
416
email: v_lie@hotmail.com
417
418
AMPK
ini
yang
membedakan
Gambar. Kerangka konsep perbandingan kemoterapi dengan kombinasi metformin dan kemoterapi dalam
pengobatan kanker paru.
419
WHO. Cancer [Internet]. 2013 Jan [cited on 2013 Dec 6]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.
2.
WHO. Lung cancer estimated incidence, mortality and prevalence worldwide in 2012 [Internet]. 2013 June 12 [cited on 2013 Dec 6]. Available from: http://globocan.
iarc.fr/Pages/fact_sheets_cancer.aspx.
3.
NHS. Lung cancer [Internet]. 2013 Aug 2 [cited on 2013 Dec 6]. Available from: http://www.nhs.uk/Conditions/Cancer-of-the-lung/Pages/Introduction.asp.
4.
John R, Ross H. Economic value of disability-adjusted life years lost to cancers [Internet]. [cited on 2013 Dec 6]. Available from: http://media.marketwire.com/
attachments/EZIR/627/18192_FinalJournalManuscript.pdf.
5.
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrin Met. 2013; 24(9): 469.
6.
Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol. 2007; 63 (2); 172-82.
7.
Cetin K, Ettinger DS, Hei YJ, Malley CDO. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and
end results program. Clin Epidemiol. 2011; 3: 139-48.
8.
Tseng SC, Huang YC, Chen HJ, Chiu HC, Huang YJ, Wo TY. Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair
cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel. Biochemical Pharmacology. 2013; 85: 583-94.
9.
Tan BX, Yao WX, Ge J, Peng XC, Du XB, Zhang R, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients
with type 2 diabetes. Cancer 2011; 117(22): 5103-11.
10. CDC - Lung cancer risk factors [Internet]. 2013 August 6 [cited 2013 Dec 7]. Available from: http://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm.
11. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: Roadmap for therapies. Eur Respir J. 2009; 33: 1485-97.
12. Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacology & Therapeutics [Internet]. 2013 Oct 9
[cited 2013 Dec 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24121058
13. Wojtalla A, Arcaro A. Targeting phophoinositide-3-kinase signalling in lung cancer. Critical Reviews in Oncology/Hematology. 2011; 80: 278-90.
14. Lung Cancer Home Page National Cancer Institute [Internet]. [cited 2013 Dec 7]. Available from: http:// www.cancer.gov/cancertopics/types/lung.
15. Sarris EG, Saif MW, Syrigos KN. The biological role of PI3K pathway in lung cancer. Pharmaceuticals. 2012; 5: 1236-64.
16. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev. 2009; 23: 537-48.
17. Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, et al. Hereditary gynecological tumor associated with Peutz-Jeghers syndrome (review). Oncol Lett.
2013; 6(5): 1184-8.
18. Han D, Li SJ, Zhu YT, Liu L, Li MX. LKB1/AMPK/mTOR signalling pathway in non-small cell lung cancer. Asian Pac J Cancer Prev. 2013; 14(7): 4033-9.
19. Shaw RJ. LKB1 and AMPK control of mTOR signalling and growth. Acta Physiol (Oxf ). 2009; 196(1): 65-80.
20. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, et al. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse
association of AMPK and adhesion pathways with recurrence. J Thorac Oncol. 2010; 5(12): 1894-904.
21. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: Control of metabolism and cell growth. Future Oncol. 2010; 6(3): 457-70.
22. Ying M, Guan X, Liao Z, Wei Q. Insulin-like growth factor-1 receptor targeted therapy for non-small cell lung cancer: A mini review. Am J Transl Res. 2009; 1(2): 101-14.
23. Cao H, Wang G, Meng L, Shen H, Feng Z, Liu Q, et al. Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: A meta-analysis. PloS ONE.
2012; 7(11): 49884. doi:10.1371/journal.pone.0049884
24. Chen B, Liu S, Xu W, Wang X, Zhao W, Wu J. IGF-1 and IGFBP-3 and the risk of lung cancer: A meta-analysis based on nested case-control studies. Journal of
Experimental & Clinical Cancer Research. 2009; 28: 89. doi:10.1186/1756-9966-28-89.
25. Xie Z, Dong Y, Scholz R, Neumann D, Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C- is required for metformin-enhanced activation of the
AMP-activated protein kinase in endothelial cells. Circulation. 2008; 117: 959-62.
26. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer
Res Treat. 2010; 123: 271-9.
27. McCarty MF. Metformin may antagonize Lin28 and/ or Lin28 activity, thereby boosting let-7 levels and antagonizing cancer progression. Medical hypotheses. 2012;
78: 262-9.
28. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res. 2010;
3(9): 1066-76.
29. Meng D, Yuan M, Li X, Chen L, Yang J, Zhao X. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with metaanalysis. Lung Cancer. 2013; 81: 1-10.
30. Iglesias DA. Direct effects of metformin on PI3K and Ras signaling in endometrial cancer. UT GSBS Dissertations and Theses. 2012; 1-103.
31. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 2012;
12(410): 1-7.
32. Currie CJ, Poole CD, Jones SJ, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes. Diabetes Care. 2012;
35(2): 299-304.
33. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer
cell types. Cancer Res. 2011; 71(9): 3196-201.
34. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad
Sci USA. 2013; 110(3): 972-7.
35. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. 11th ed. USA: McGraw-Hill; 2009.
36. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes & Metabolism. 2011; 37: 90-6.
420